Bajaj Healthcare gets TGA’s approval for API Manufacturing Site in Gujarat

07 Dec 2024 Evaluate

Bajaj Healthcare has received approval from Therapeutic Goods Administration (TGA), Australia for its API Manufacturing Site situated at Vadodara, Gujarat.  The said site has already received approval from USFDA (U.S. Food and Drug Administration) and EU.

This is another major milestone achieved for the site and the company in achieving the vision of becoming a Global supplier of APIs. This recognition by TGA of Site’s manufacturing and compliance capabilities would pave the path for direct supplies of API to this stringent regulated territory as well as supplies to drug product manufacturers across the globe, who are supplying their finished product in the territory of Australia and New Zealand. Post this recognition, the company is eyeing to attract more CDMO contracts from existing and new clients.

Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.


Bajaj Healthcare Share Price

559.00 89.90 (19.16%)
18-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1800.30
Dr. Reddys Lab 1275.05
Cipla 1472.05
Lupin 2098.70
Zydus Lifesciences 979.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.